Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231231 · ClinicalTrials.gov registry record · Phase 3
Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)
A Phase 3 study, sponsored by Cordis US.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
NCT00231231 is a Phase 3 study that has completed, run by Cordis US. The registered enrollment target is 1,500 participants.
The verdict
NCT00231231, a Phase 3 study, has completed, sponsored by Cordis US.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease during peri-approval/initial commercialization in relation to the outcomes of the Sapphire Clinical Trial. The devices to be utilized are the Cordis PRECISE Nitinol Stent Systems and the Cordis ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW).
Interventions
- DEVICE -PRECISE Nitinol Stent System (5F, 5.5F and 6F)
- DEVICE ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231231
The ClinicalTrials.gov registry entry for NCT00231231 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cordis US, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which -PRECISE Nitinol Stent System (5F, 5.5F and 6F) is the first listed.
NCT00231231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00231231 about?
NCT00231231 is a clinical study titled "Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)". The primary objective of this study is to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease during peri-approval/initial commercialization in relation to the outcomes of the Sapphire Clinical Trial. The devices to be utilized are the Cordis...
What is the current status of trial NCT00231231?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2004-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00231231?
The interventions under investigation include: -PRECISE Nitinol Stent System (5F, 5.5F and 6F) (DEVICE), ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW) (DEVICE).
Who is sponsoring clinical trial NCT00231231?
This trial is sponsored by Cordis US, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.